<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468454</url>
  </required_header>
  <id_info>
    <org_study_id>08-006211</org_study_id>
    <nct_id>NCT01468454</nct_id>
  </id_info>
  <brief_title>Phase II Safety and Efficacy Study of F-DOPA PET/CT in Children With Hyperinsulinemic Hypoglycemia</brief_title>
  <acronym>F-DOPA PET</acronym>
  <official_title>A Phase II Safety and Efficacy Study of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Children With Hyperinsulinemic Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these
      children may require surgery to remove part or all of their pancreas. In this study,
      researchers will test how well a radioactive drug, 18-labeled L-fluorodeoxyphenylalanine
      (called F-DOPA) can detect a form of hyperinsulinism (focal HI) that may be cured by surgery.
      Eligible participants in this study will have positron emission tomography/computerized
      tomography (PET/CT) scans with F-DOPA prior to surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For children with congenital hyperinsulinism (CHI), low blood sugar is caused by cells in the
      pancreas that release too much insulin. Some children with CHI have these cells throughout
      their pancreas (called diffuse disease); others have them located in specific areas of the
      pancreas (called focal disease). Children who have focal disease located in specific areas of
      the pancreas may be cured with surgery. F-DOPA is a radioactive drug that is picked up by
      these cells and used for positron emission tomography (or PET), an imaging technique used in
      nuclear medicine departments. In this study, researchers will validate the efficacy and
      safety of using PET/CT with F-DOPA in the pre-operative localization of focal disease in
      children with hyperinsulinism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of 18F-DOPA PET/CT scans to detect focal lesions in infants and children with congenital hyperinsulinism</measure>
    <time_frame>within 7 days following PET</time_frame>
    <description>To determine the accuracy of localization, sensitivity, specificity of 18F-DOPA PET/CT in detecting a focal lesion in children with HI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of 18F-DOPA PET/CT scan</measure>
    <time_frame>up to 4 weeks after F-DOPA administration or hospital discharge</time_frame>
    <description>To further evaluate the safety of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET/CT imaging in infants and children with congenital hyperinsulinism
- subjects are monitored clinically for any signs or symptoms of adverse events for 72 hours post PET. Adverse events are documented and followed to resolution</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Congenital Hyperinsulinism (CHI)</condition>
  <condition>Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)</condition>
  <arm_group>
    <arm_group_label>(18F-DOPA) PET/CT imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obtain safety and efficacy data on the use of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET imaging in children with HI for the clinical indication of localizing a focal lesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18 F-DOPA</intervention_name>
    <description>one time injection of 0.08 - 0.16 mCurie/kg of 18F-DOPA</description>
    <arm_group_label>(18F-DOPA) PET/CT imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants and children with a clinical diagnosis of hyperinsulinism who are suspected to
             have focal disease and are surgical candidates for pancreatectomy

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Any other major illness or condition that might substantially increase the risk
             associated with the subject's participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa J States, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.chop.edu/service/congenital-hyperinsulinism-center/home.html</url>
    <description>The Congenital Hyperinsulinism Center at The Children's Hospital of Philadelphia</description>
  </link>
  <reference>
    <citation>Hardy OT, Hernandez-Pampaloni M, Saffer JR, Suchi M, Ruchelli E, Zhuang H, Ganguly A, Freifelder R, Adzick NS, Alavi A, Stanley CA. Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J Pediatr. 2007 Feb;150(2):140-5.</citation>
    <PMID>17236890</PMID>
  </reference>
  <reference>
    <citation>Hardy OT, Hernandez-Pampaloni M, Saffer JR, Scheuermann JS, Ernst LM, Freifelder R, Zhuang H, MacMullen C, Becker S, Adzick NS, Divgi C, Alavi A, Stanley CA. Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab. 2007 Dec;92(12):4706-11. Epub 2007 Sep 25.</citation>
    <PMID>17895314</PMID>
  </reference>
  <reference>
    <citation>Hardy OT, Litman RS. Congenital hyperinsulinism - a review of the disorder and a discussion of the anesthesia management. Paediatr Anaesth. 2007 Jul;17(7):616-21. Review.</citation>
    <PMID>17564642</PMID>
  </reference>
  <reference>
    <citation>Peranteau WH, Ganguly A, Steinmuller L, Thornton P, Johnson MP, Howell LJ, Stanley CA, Adzick NS. Prenatal diagnosis and postnatal management of diffuse congenital hyperinsulinism: a case report. Fetal Diagn Ther. 2006;21(6):515-8. Epub 2006 Sep 12.</citation>
    <PMID>16969006</PMID>
  </reference>
  <reference>
    <citation>Chevalme, Yanna-Marina et al. FDOPA-(18F): a PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union. Braz. arch. biol. technol. [online]. 2007, vol.50, n.spe [cited 2011-10-06], pp. 77-90 . Available from: &lt;http://www.scielo.br/scielo.php?script=sci_arttext&amp;pid=S1516-89132007000600009&amp;lng=en&amp;nrm=iso&gt;. ISSN 1516-8913. http://dx.doi.org/10.1590/S1516-89132007000600009.</citation>
  </reference>
  <results_reference>
    <citation>Laje P, States LJ, Zhuang H, Becker SA, Palladino AA, Stanley CA, Adzick NS. Accuracy of PET/CT Scan in the diagnosis of the focal form of congenital hyperinsulinism. J Pediatr Surg. 2013 Feb;48(2):388-93. doi: 10.1016/j.jpedsurg.2012.11.025.</citation>
    <PMID>23414871</PMID>
  </results_reference>
  <results_reference>
    <citation>Laje P, Palladino AA, Bhatti TR, States LJ, Stanley CA, Adzick NS. Pancreatic surgery in infants with Beckwith-Wiedemann syndrome and hyperinsulinism. J Pediatr Surg. 2013 Dec;48(12):2511-6. doi: 10.1016/j.jpedsurg.2013.05.016.</citation>
    <PMID>24314195</PMID>
  </results_reference>
  <results_reference>
    <citation>Peranteau WH, Palladino AA, Bhatti TR, Becker SA, States LJ, Stanley CA, Adzick NS. The surgical management of insulinomas in children. J Pediatr Surg. 2013 Dec;48(12):2517-24. doi: 10.1016/j.jpedsurg.2013.04.022.</citation>
    <PMID>24314196</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>November 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <disposition_first_submitted>August 7, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 7, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 12, 2013</disposition_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Lisa States</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Congenital Hyperinsulinism (CHI)</keyword>
  <keyword>hyperinsulinism</keyword>
  <keyword>Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)</keyword>
  <keyword>CHI</keyword>
  <keyword>PHHI</keyword>
  <keyword>Pancreatectomy</keyword>
  <keyword>18F-DOPA</keyword>
  <keyword>PET/CT scan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Hyperinsulinism</mesh_term>
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydroxyphenylalanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

